Rebecca Schulte

Rebecca Schulte

Auto-generated profile, based on publicly available information

Rebecca Schulte

Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2021 in Women's Health Issues
Verified
Journal Article
Closed access
JPJulia C. Phillippi
Julia C. Phillippi
RSRebecca Schulte
Rebecca Schulte
KBKemberlee Bonnet
Kemberlee Bonnet
DSDavid D. Schlundt
David D. Schlundt
WCWilliam O. Cooper
William O. Cooper
SPStephen W. Patrick
Stephen W. Patrick

17 October 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
RWRamara Walker
Ramara Walker
RSRebecca Schulte
Rebecca Schulte
APAndrea M. Pallotta
Andrea M. Pallotta
LTLarisa G. Tereshchenko
Larisa G. Tereshchenko
VCVictoria A. Criswell
Victoria A. Criswell
MRMichael B. Rothberg
Michael B. Rothberg
Background: Community-acquired pneumonia (CAP) is a leading cause of hospitalizations and mortality in the US. Overuse of extended spectrum antibiotics (ESA) for CAP contributes to antimicrobial resistance. The 2019 Infectious Diseases Society of America/American Thoracic Society CAP guidelines emphasize de-escalation of ESA following negative cultures, early switch to oral (PO) antibiotics, and limited duration of therapy (DOT). This study describes clinicians’ acceptance of an infectious diseases-trained (ID) pharmacist-led stewardship recommendations in hospitalized patients with CAP. Methods: This prospective, single-arm, cohort study included adults admitted with a diagnosis of pneumonia to six Cleveland Clinic hospitals receiving ID pharmacist-led stewardship recommendations. The ID pharmacist provided recommendations for ESA de-escalation, DOT, intravenous (IV) to PO transition, and antimicrobial discontinuation. Descriptive statistics were used to describe clinician acceptance rates. Results: From November 1, 2022, to January 31, 2024, the ID pharmacist made recommendations for 685 patient encounters to 327 clinicians. Of these patients, 52% received an ESA and 15% had severe CAP. There were 959 recommendations: ESA de-escalation (19%), DOT (46%), IV to PO transition (19%), antimicrobial discontinuation (13%), and other (3%). Clinicians accepted 693 recommendations (72%): IV to PO transition (148/184, 80%), ESA de-escalation (141/181 78%), antimicrobial discontinuation (94/128, 73%), DOT (286/437, 65%), and other (24/29, 83%). Conclusion: Clinicians were generally receptive to ID pharmacist-led CAP recommendations with an overall acceptance rate of 72%. Prescribers were most receptive to recommendations for IV to PO conversion and least receptive to limiting DOT.